DIRS.INFO The most relevant business & tech news

☆ Putin to meet Xi in China as world convulses from global conflicts
▼ + stars: | 2024-05-14 | by ( Simone Mccarthy | ) edition.cnn.com time to read: +10 min

Pyongyang – which has an economy almost entirely dependent of China – is believed by Western governments to be aiding Russia with war supplies. Xi has ramped up his calls for Europe and other countries to help the world avoid a “Cold War,” suggesting they resist what Beijing sees as US efforts to contain China. They have also criticized Israel and the United States – converging with mounting global backlash, especially across the Global South against Israel’s war. The conflict has also impacted how China and Russia view their relations with countries there, he added. China “wants to use Russia” for its aims, but Russia is making China weak, he said.

Persons: Xi Jinping, Vladimir Putin, Putin, –, It’s, China –, Xi, France –, Jens Stoltenberg, Sergei Guneyev, ”, Li Mingjiang, Manoj Kewalramani, Russia doesn’t, Stringer, Gaza —, Sergey Lavrov, presser, Wang Yi, Israel, “, Privately, Shen Dingli, China “, Alexander Dugin, Donald Trump, Li Organizations: Hong Kong CNN, West, NATO, Forum, Singapore’s Nanyang Technological University, EU, Takshashila, Boys, Getty, United, Global, Shanghai Cooperation Organization, Russia, Weibo, Moscow, CNN Locations: Hong Kong, China, Russian, Gaza, Ukraine, Moscow, Washington, Iran, North Korea, Pyongyang, Russia, Tehran, Beijing, Europe, France, Serbia, Hungary, Bangalore, Rafah, AFP, Israel, United States, Kewalramani, South, Taiwan, Shanghai, Singapore

☆ Vertex Pharma CEO Kewalramani sits down with Jim Cramer
▼ + stars: | 2024-02-08 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Vertex Pharma CEO Kewalramani sits down with Jim CramerVertex Pharma President and CEO Dr. Reshma Kewalramani joins 'Mad Money' host Jim Cramer to talk sickle cell gene therapy, cystic fibrosis treatments and more.

Persons: Kewalramani, Jim Cramer, Reshma Kewalramani Organizations: Vertex Pharma, Pharma

☆ Vertex non-opioid painkiller shows positive results in critical late-stage trial on acute pain
▼ + stars: | 2024-01-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Acute pain is usually caused by injury, surgery, illness, trauma or painful medical procedures and is likely to ease with time. Around 80 million patients are prescribed a medicine for their moderate-to-severe acute pain every year in the U.S., Vertex said in a release. Last year, the company's painkiller produced positive results in a mid-stage trial in diabetes patients suffering from a chronic nerve condition. Those two procedures are commonly used in studies of people with acute pain. Jefferies analyst Michael Yee said the drug's failure to meet that goal is in line with expectations and that overall, the late-stage trial results released Tuesday are positive.

Persons: Reshma Kewalramani, painkiller, Michael Yee Organizations: Vertex Pharmaceuticals, Food and Drug, Wall Street, CRISPR Therapeutics, Jefferies Locations: Boston, U.S

☆ BRICS Summit: Who stands to benefit from Russia-friendly bloc's expansion?
▼ + stars: | 2023-08-21 | by ( Simone Mccarthy | ) edition.cnn.com time to read: +10 min

The group of Brazil, Russia, India, China and South Africa has never been more prominent on the world stage. Russia’s leader can’t attend the summit because host country South Africa would be obliged to arrest him for alleged war crimes. But nonetheless that family is now entertaining formal bids from nearly two dozen countries to join their bloc of major emerging economies. It held its first summit in 2009 with four members and then added South Africa the following year. An expansion, instead of making the group more potent, could also make it “more unwieldy and ineffective” with more contrasting positions between members, he added.

Persons: can’t, It’s, Russia’s Vladimir Putin –, Putin, Cyril Ramaphosa, BRICS, ” “, Chen Xiaodong, Bhaso, “, China’s Xi, India’s Narendra Modi, Brazil’s Luiz Inacio Lula da Silva, –, Goldman Sachs, Jim O’Neill, BRICS Anil Sooklal, Mihaela Papa, ”, Xi, Yun Sun, Putin –, Manoj Kewalramani, Kewalramani, Modi, Lula, Ramaphosa, Yevgeny Prigozhin, Wagner, Rubens Duarte Organizations: CNN, West, Washington, Sunday, University of Johannesburg, New Development Bank, United Arab, Tufts University, Western, China Program, Stimson, NATO, Takshashila, United Nations Locations: South Africa, Brazil, Russia, India, China, Beijing, United States, New Delhi, Ukraine, African, Argentina, Mexico, Iran, Saudi Arabia, United Arab Emirates, Egypt, Nigeria, Bangladesh, South, Washington, BRICS, Bangalore, Johannesburg, Russian, – China, Africa, Europe

☆ India and China are kicking out each others' journalists in latest strain on ties
▼ + stars: | 2023-06-06 | by ( Simone Mccarthy | ) edition.cnn.com time to read: +8 min

Visa spatOn Sunday, Xinhua published a first-person account from Hu Xiaoming, the state agency’s New Delhi bureau chief since 2017, describing the “torment” of Chinese reporters’ “visa hassle” in India. A spokesperson for India’s Ministry of External Affairs on Friday declined to comment on the number of Chinese journalists in the country when asked in a regular briefing. “All foreign journalists, including Chinese journalists, have been pursuing journalist activities in India, without any limitations or difficulties in reporting,” spokesperson Arindam Bagchi said. Bagchi did not confirm that any Indian reporters had lost accreditation in China, but said such reporters had faced difficulties doing their jobs there. Because Chinese reporters are working for state media outlets, New Delhi is also likely looking at them as “state actors,” according to Kewalramani.

Persons: Mao Ning, It’s, Hu Xiaoming, ”, ’, Hu, Arindam Bagchi, Bagchi, Ananth Krishnan, Anshuman Mishra, Narendra Modi’s, “, Manoj Kewalramani, Modi, Xi Jinping, Kewalramani Organizations: Hong Kong CNN —, Beijing, CNN, Foreign, Washington, Visa, Xinhua, India’s Ministry, Affairs, Ministry, Prasar, Foreign Ministry, BBC, Takshashila, Huawei, Shanghai Cooperation Organization – Locations: Hong Kong, Hong Kong CNN — India, China, New Delhi, Beijing, India, Aksai Chin, Ladakh, Delhi, India China, Mumbai, British, Bengaluru, If, United States, Japan, US, Australia, Jammu, Kashmir, Pakistan

☆ A year after hitting a record, here are the biggest Nasdaq-100 winners and losers
▼ + stars: | 2022-11-20 | by ( Fred Imbert | ) www.cnbc.com time to read: +3 min

On Nov. 19, 2021, the Nasdaq-100 index — which is made up of the 100-largest Nasdaq Composite stocks — hit a record closing high of 16,573.34. DocuSign and Zoom Video have fallen more than 80% and 67%, respectively, since the Nasdaq-100 reached its record high. Megacap stocks such as Meta Platforms , Tesla and Amazon have also plunged over the past 12 months, in part due to their high valuations. Vertex Pharmaceuticals has rallied 69.5% since the Nasdaq-100 closed at a record. O'Reilly Automotive, T-Mobile and Gilead Sciences are also among the big Nasdaq-100 winners over the year since the Nasdaq closed at an all-time high.

☆ Gene-editing companies are growing thanks to fast-paced science, even as biotech faces a downturn
▼ + stars: | 2022-10-12 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +8 min

CRISPR companies are faring better by producing faster and more dramatic clinical results. A layoff tracker from Fierce Biotech counts at least 90 drug companies that have laid off staff in 2022. Gene-editing biotechs have avoided the brunt of the downturn because of fast clinical successIntellia Therapeutics is developing CRISPR-based gene-editing medicines that could cure diseases. Just in the past month, CRISPR Therapeutics moved into a swanky new headquarters in Boston that can house up to 1,000 people. BeamTo be sure, 2022 hasn't been smooth sailing for the CRISPR companies.

☆ We went inside the lab at Vertex, a company that dodged the market downturn to become one of the best-performing biotechs of 2022
▼ + stars: | 2022-09-21 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +10 min

A mosaic of human cells inside Vertex Pharmaceuticals' cell and gene-therapy laboratory. The four-story, 267,000-square-foot space is home to Vertex's cell and gene-therapy unit, with about 375 people now residing in the modern-industrial building. That has led to going after unrelated diseases like sickle cell, diabetes, muscular dystrophy, kidney disease, and pain. For instance, Vertex's approach to sickle cell is led by its CRISPR gene-editing program. Vertex PharmaceuticalsThe next test of Vertex's strategy will be an experimental treatment called exa-cel, its CRISPR gene-editing program for sickle cell.

☆ China and Russia present united front at regional summit despite differences
▼ + stars: | 2022-09-16 | by ( Nectar Gan | Rhea Mogul | ) edition.cnn.com time to read: +8 min

In recent months, China has offered Russia tacit support and stepped up economic assistance to its neighbor, boosting bilateral trade to a record high. But Kewalramani said the SCO could provide a "space (for India) to engage with China and Russia." "Particularly, being on the table while China and Russia are together, because the closer that relationship gets, the trickier it gets for India," he said. Since 2019, Iran, Russia and China have held three joint naval drills amid deepening ties. But some experts say in its current state, the SCO is not really the ideal platform for China and Russia to push that anti-West world order.

Search resuls for: "Kewalramani"

9 mentions found